By Inga Hansen, executive editor of MedEsthetics Recently, we had the opportunity to speak with Brent Saunders, CEO of Allergan, about the company’s operations following its acquisition by Actavis, the proposed merger with Pfizer and what he feels are the most promising trends for the medical aesthetics industry. MedEsthetics: Earlier this year Allergan was acquired by Actavis. What kind of feedback are you getting from customers since the merger? Saunders: “When I’m out talking to physicians and consumers, most of the feedback I get is that they’ve been impressed with the integration in that they haven’t noticed it. They’re also very excited about the commitment the new Allergan has brought to aesthetic medicine and plastic surgery—our investments in product flow, our investments in innovation, and our investments in training and education and in R&D.” MedEsthetics: Are there any new products coming to market or on the horizon that you are particularly excited about? Saunders: “We will continue to look at new indications for Botox. We will continue to bring—and complete—a line of fillers around the Juvederm VOLUMA brand and we are researching new indications in that area. We continue to invest in R&D in our breast implant business and then, of course, the big news this year was that we acquired KYBELLA for submental fat. We are now beginning to look at other indications and other uses for research studies for KYBELLA.” Read more at MedEsthetics.